Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment
Gastroenterol Hepatol. 2020 Dec;43(10):649-658.
doi: 10.1016/j.gastrohep.2020.04.004.
Epub 2020 Jun 27.
[Article in
English,
Spanish]
Authors
Manuel Barreiro-de Acosta
1
, Ignacio Marín-Jimenez
2
, Iago Rodríguez-Lago
3
, Francisco Guarner
4
, Eloy Espín
5
, Isabel Ferrer Bradley
6
, Ana Gutiérrez
7
, Belén Beltrán
8
, María Chaparro
9
, Javier P Gisbert
9
, Pilar Nos
8
; en representación de GETECCU
Affiliations
- 1 Unidad EII, Servicio de Aparato Digestivo, Hospital Clínico Universitario de Santiago, Santiago de Compostela, España. Electronic address: manubarreiro@hotmail.com.
- 2 Servicio de Aparato Digestivo, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Universitario Gregorio Marañón, Madrid, España.
- 3 Unidad de EII, Servicio de Aparato Digestivo, Hospital de Galdakao, Galdakao, España; Instituto de Investigación Sanitaria Biocruces Bizkaia, Barakaldo, España.
- 4 Grupo de Fisiología y Fisiopatología Digestiva, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, España.
- 5 Unidad de Cirugía Colorrectal, Servicio de Cirugía General, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
- 6 Unidad de EII, Servicio Medicina Digestiva, Hospital de Manises, Valencia, España.
- 7 Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, España.
- 8 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, España; Unidad de EII, Servicio de Medicina Digestiva, Hospital Universitario y Politécnico La Fe, Valencia, España.
- 9 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, España; Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Madrid, España.
Abstract
Pouchitis treatment is a complex entity that requires a close medical and surgical relationship. The elective treatment for acute pouchitis is antibiotics. After a first episode of pouchitis it is recommended prophylaxis therapy with a probiotic mix, nevertheless it is not clear the use of this formulation for preventing a first episode of pouchitis after surgery. First-line treatment for chronic pouchitis is an antibiotic combination. The next step in treatment should be oral budesonide. Selected cases of severe, chronic refractory pouchitis may benefit from biologic agents, and anti-TNF α should be recommended as the first option, leaving the new biologicals for multi-refractory patients. Permanent ileostomy may be an option in severe refractory cases to medical treatment.
Keywords:
Colitis ulcerosa; Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Pouchitis; Reservoritis; Ulcerative colitis.
Copyright © 2020 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Acute Disease
-
Advisory Committees
-
Algorithms
-
Anti-Bacterial Agents / therapeutic use*
-
Biological Products / therapeutic use
-
Budesonide / therapeutic use
-
Chronic Disease
-
Ciprofloxacin / therapeutic use
-
Colitis, Ulcerative / surgery*
-
Crohn Disease
-
Drug Resistance
-
Enema / methods
-
Humans
-
Ileostomy / methods
-
Immunosuppressive Agents / therapeutic use
-
Metronidazole / therapeutic use
-
Postoperative Complications / prevention & control
-
Postoperative Complications / therapy*
-
Pouchitis / prevention & control
-
Pouchitis / therapy*
-
Probiotics / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Secondary Prevention / methods
-
Spain
Substances
-
Anti-Bacterial Agents
-
Biological Products
-
Immunosuppressive Agents
-
Metronidazole
-
Budesonide
-
Ciprofloxacin